IRIS Accounts Production v24.3.2.46 03930219 Board of Directors 1.1.23 31.12.23 31.12.23 true false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh039302192022-12-31039302192023-12-31039302192023-01-012023-12-31039302192021-12-31039302192022-01-012022-12-31039302192022-12-3103930219ns15:EnglandWales2023-01-012023-12-3103930219ns14:PoundSterling2023-01-012023-12-3103930219ns10:Director12023-01-012023-12-3103930219ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3103930219ns10:SmallEntities2023-01-012023-12-3103930219ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3103930219ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3103930219ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3103930219ns10:FullAccounts2023-01-012023-12-3103930219ns5:CurrentFinancialInstruments2023-12-3103930219ns5:CurrentFinancialInstruments2022-12-3103930219ns5:ShareCapital2023-12-3103930219ns5:ShareCapital2022-12-3103930219ns5:SharePremium2023-12-3103930219ns5:SharePremium2022-12-3103930219ns5:RetainedEarningsAccumulatedLosses2023-12-3103930219ns5:RetainedEarningsAccumulatedLosses2022-12-3103930219ns10:RegisteredOffice2023-01-012023-12-3103930219ns5:CostValuation2022-12-3103930219ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3103930219ns5:WithinOneYearns5:CurrentFinancialInstruments2022-12-31
REGISTERED NUMBER: 03930219 (England and Wales)


















Unaudited Financial Statements for the Year Ended 31 December 2023

for

iPlato Limited

iPlato Limited (Registered number: 03930219)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Balance Sheet 1

Notes to the Financial Statements 2


iPlato Limited (Registered number: 03930219)

Balance Sheet
31 December 2023

2023 2022
Notes £    £   
FIXED ASSETS
Investments 4 1,602 1,602

CURRENT ASSETS
Debtors 5 1,306,330 1,361,737
Cash at bank 2,320 1,170
1,308,650 1,362,907
CREDITORS
Amounts falling due within one year 6 (5,645 ) (47,437 )
NET CURRENT ASSETS 1,303,005 1,315,470
TOTAL ASSETS LESS CURRENT LIABILITIES 1,304,607 1,317,072

CAPITAL AND RESERVES
Called up share capital 338 338
Share premium 82,769 82,769
Retained earnings 1,221,500 1,233,965
SHAREHOLDERS' FUNDS 1,304,607 1,317,072

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 April 2025 and were signed on its behalf by:





D Vahdat - Director


iPlato Limited (Registered number: 03930219)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

iPlato Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 03930219

Registered office: Millbank Tower
21-24 Millbank
London
SW1P 4QP

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

The financial statements for the year ended 31 December 2022 were prepared in accordance with for the FRS 101 for the first time however previously the financial statements had been prepared in accordance with FRS 102 therefore the directors have taken the option to restate the opening reserves and comparative amounts by retrospectively applying FRS 102 as if it had always applied in accordance with paragraph 35.2 of FRS 102 and not applied the first-time adoption procedures in full. There is no effects of restatement in the financial statements.

Preparation of consolidated financial statements
The financial statements contain information about iPlato Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its parent, Huma Therapeutics Limited, 13th Floor Millbank Tower, 21-24 Millbank, London, England, SW1P 4QP.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

iPlato Limited (Registered number: 03930219)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

2. ACCOUNTING POLICIES - continued

Investments
Investments are classified as financial assets measured at fair value through profit or loss. They are not held for trading and the Company subsequently measures all equity investments at fair value, with the movements recognised in the statement of profit or loss.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2023
and 31 December 2023 1,602
NET BOOK VALUE
At 31 December 2023 1,602
At 31 December 2022 1,602

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Amounts owed by group undertakings 1,304,206 1,361,631
Other debtors 2,124 106
1,306,330 1,361,737

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors - 17
Taxation and social security - 40,570
Other creditors 5,645 6,850
5,645 47,437

7. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Huma Therapeutics Limited a private company, limited by shares, registered in England and Wales. Registered number is 07725451 and registered office is 13th Floor Millbank Tower, 21-24 Millbank London, United Kingdom, SW1P 4QP.

8. AUDIT EXEMPTION

For the year ending 31/12/2023, the company was entitled to exemption from audit under section 479A of the Companies Act 2006 relating to subsidiary companies. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges responsibility for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.